and Sarah. corporate Thank and Good quarter update of call second morning you, the welcome for XXXX. financial everyone our to
on and development have team. goals and perseverance, for XMT-XXXX, progress of moving challenges work patients. achieving the clinical Because the DeSchuytner, on is be a towards of significant your I'm available delivered our our commitment the been pipeline significantly Despite our exciting COVID-XX into of Mersana. made the including entire Strategy. Brian prepared the the for first The half team well Joining me we milestones agency data VP of with positioned of pipeline today Mersana which and for XMT-XXXX our transformative our executive very proud clinical financings vision and against benefit we of Mersana. the multiple questions. has year the of operating executed as their advancing important important field candidates, have rest reached XXXX Product remarks Finance Senior cancer environment, team in will It
milestones. summarize me Let those
neuropathy ovarian and active conference, March the of Gynecologic of and at on dose, in demonstrated and in agent the presented the square ocular due canceled that our escalation patients lieu at is lung data milligrams established we both both adenocarcinoma We which observed was tolerated the COVID-XX. XX the severe other webcast XMT-XXXX, of neutropenia, this well meter dose for platforms. First, the XX, maximum per without tolerated Oncology Society dose to ADC oral with toxicity presentation at and
with demonstrated proof-of-concept we pretreated complete ovarian cancer for in heavily Second, XMT-XXXX XX% XX% response response rate. including rate of patients a a
ASCO of cancer patients, associated with key XX. rate webcast XX%. in data reminder, X% a presented to and of with As single-agent is platinum-resisted on a a were investigator care ovarian the May response standard at These chemotherapy a
one demonstrated expansion disease escalation have study. we multiple patients stable PR pretreated activity in heavily Third, of prolonged proof the in with in and adenocarcinoma dose dose lung XMT-XXXX with and
For filed presented escalation dose the with from the dosing to tolerated the maximum rapidly the The objective clinically and IND cleared to of was at preclinical and evaluate XMT-XXXX, differentiation supported XX. and we XMT-XXXX June initiated potential the conference XMT-XXXX. virtual dose on data of AACR reach patient a
free XXX-fold immune immunosynthen our and data as ADC significantly a on data of tolerated supporting preclinical at and potential continue the conference STING-agonist increased for well reduction targets systemic potency compared to has We the significantly Immunosynthen memory XX. deliver improved data activation. of platform. when AACR STING-agonist tumor-specific virtual We across shows unconjugated over administered other These the demonstrate therapeutic into These to targeted doses agonist effect pent-up hallmarks that lower antitumor pre-clinical as intravenously as also immune that cytokines a June have well well to Immunosynthen models index. presented advance robust multiple continued and as
also have agent unmet potential patients need. with first-in-class generate for high a IND-enabling have our to ADC impact supporting positive continue medical this the BX advanced data to We studies into and of exciting
good strong second at life-changing With a $XXX early proof-of-concept provide additional a cancel an in entices million our cash and April a that transaction of gross a activity executed ovarian balance public in successful a Mersana June candidate financing with need. at added in combined platform, a position experienced approaching strengthening we molecule and patients a in adenocarcinoma, achieve a to position differentiation candidate deferential to for to Lastly, team proceeds first-in-class potential in program proof cancer lung in sheet. compelling is in pipeline selection,
Let me for year. milestones now of I'll second again. the outline begin efforts the half and with upcoming XMT-XXXX our
guidance with of to the But year. for is XMT-XXXX the study We continue patients over end had cohort. to originally enthusiasm we to the XXXX. this with expect course of cancer enroll to to investigator about portion ovarian in XX of XMT-XXXX, the exceed objective expansion expansion Our XX because by of planned recruit
achieved to as registration. we actively are the options, the few XMT-XXXX with platinum some sold on in defining and path PARP key Given bevacizumab well inhibitors, responses patients as with having working
FDA as is the of XXXX there calls Our to that high as meet on around precedent, believe, the accelerated need platinum-resistant plan regulatory with excellent ovarian cancer. on We medical end their is gain an and based well with to unmet in discussions feedback. goal based approval
regarding costs a ovarian on longer-term registration Canada end provide in larger comprehensive of the interactions longer to we are FDA operational significantly patients; expected registration-enabling From of cancer follow-up development update year, and in FDA a the given study, discussion life the the expanding plan sites also and well cycle and preparations the for plan life our addition as the the the We the to standpoint, the XMT-XXXX. Australia. our and developing management Europe, around for in are number longer-term we number an In cycle plan management of XMT-XXXX plan. as U.S.
the more details exact We a will of this time. provide later value at regarding update
September. Note As and Breast Program for first Research initial is on next Oncology presentation e-poster made ASCO that a Virtual poster will August. ovarian X:XX host for key that Research Tennessee XXXX, cancer as The plan is be be XXXX the Director, Gynecological our that update, assessment ESMO I on Cancer pleased cutoff upcoming Cannon or accepted and featuring at this patients we weeks. from am to The Sarah Erika our conference Cancer ESMO's has the report will in cutoff Congress to data a Remember date eight after was data for at for been XXth focused early to XX, scheduled call Dr. September September cycles the webcast AM. discuss live first. at The two abstract investigator, Institute only. data Hamilton, e-poster and
result additional the the [indiscernible] not at ASCO, follow-up number we incremental of presented the type list a or this are assessments an May. the will As patients be enter and small ASCO study the either of a who cutoff with at the update of of patients of clinic disclosure additional data in
XMT-XXXX Although goal incremental is about Europe is increase this the positions. ELs of awareness so investigators and disclosure this to of data,
As the disclosure as discuss XMT-XXXX. I a to provide about more as comprehensive opportunity year-end will to the the for plan set, we data path forward well provide mentioned,
patients. adenocarcinoma continue also We enroll to lung
expansion been as believe well will challenges lung of because international a XX of stated should international and coming to which of easing initiate have the rest allow and the patient restrictions the about related our certain delays difficult However, goal and outside patients, weeks competition lung XX to rate in On see of accelerate the this as recruitment to there year-end. cohort more at the cancer for positive patients achieving to to focus a due enrolling we to recruitment previously months point note, begun to by sites initiating of sites the U.S., have we predict COVID-XX COVID-XX through us year. intense in be lung in the
geographic also allowed to us international broaden of any diversity reemergence reach COVID-XX, potential initiation the our mitigate of and addition, both should to In regional and sites globally. domestically our
and including evaluate dose We understanding lung for the differentiation. during the are its data cohort, profile will XXXX data potential disclosure of progress our expansion gain parallel quarterly will we its for updates, continue In the to and this better calls. recruitment provide to clinical cohort next timing adenocarcinoma the expansion a planned a of to potential escalating from XMT-XXXX
the forward is adenocarcinoma and by informed sets which molecule a data in expected decision XXXX. will is reminder, both lung to we take be As in
our We development ADC also to Beyond clinical discovery immunosynthen BX-HX our ADC including and next ADC late-stage first-in-class on including advance our our an ADC candidate BX-HX achieved first with the our milestones important this our candidate program, from candidates, targeting platform. to disclosure we STING-agonist continued ADC candidate milestones and development remain platform. of reach the our immunosynthen of year, track ADC candidate
the minute management at changes Mersana. like to some Brian, to a turn take over discuss I Before call to I'd
endeavors. both to recognize role her over driving I'd First, key G&A partnerships six high-performing to initial Chief to are will critical and all very private the capable building our here, wouldn't your without contributions. and for a has thank offering. and company's new an as public her we contributing Eva all built We played Eva's playing a on including financings, as the pursue and Mersana today opportunities. She's in a Officer, Eva, in Thank key be In like she's new in contributions. and role best team. Jack, exemplary public well Eva leader years from where you, of a be team, Business moving
management changing Manufacturing like the has and Mersana's including I to multiple advise him supply scale candidates. of Kaufman VP commitment strategic as across and thank advancing and pipeline the Senior from experience leader to the many that, call to Congratulations, as we our over team Michael, development, contributions therapeutic continued be into a to and a recognize ADC built XMT-XXXX joined of bringing focus Michael pivotal this up platform Lastly, chain would overview your top they and robust technical for development process enter and I modalities, Officer. Mersana leadership, of now Michael in lead this a studies. diligently leadership with He's you joining, to in proven earlier-stage over financial Since of are to an of results. next development, XXXX, acumen. our CMC well formulation wealth your CMC under title best scale his are Michael as ADCs. as Brian a asset Chief working large with with normal will years up stage important XMT-XXXX, And we for turn DeSchuytner and on
